SPEAKERS'/CHAIRS' ABSTRACTS 153 increased tumor-associated proteolysis was observed as increased degradation of DQ-collagen IV intracellularly. When breast or colon fibroblasts were cocultured with breast or colon tumor cells, respectively, increased tumor-associated proteolysis was also observed, in this case primarily as a result of increased pericellular degradation of DQ-collagen IV. Pericellular degradation of DQ-collagen IV was increased to an even greater extent when fibroblasts, tumor cells, and macrophages were all cocultured. Thus, our findings confirm with living cells in situ that interactions among tumor and host cells can alter tumor-associated proteolysis. Furthermore, they indicate that therapeutic approaches for reducing tumor-associated proteolysis will need to target host cells and tumor cells as well as to target the interactions among host and tumor cells.
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Molecular imaging is broadly defined as the characterization and measurement of biological processes in living animals, model systems and humans at the cellular and molecular level using remote imaging detectors. In the emerging "postgenomic era," wherein functionality will be added to the vast arrays of genetic information, opportunity exists for imaging to play a significant role in basic and translational research as well as clinical care for cancer patients. Herein, future objectives are focused on adding functional information through molecular imaging. The goal is to advance patient care and our understanding of medicine through noninvasive in vivo interrogation of the cellular and molecular events mediating normal physiology, pathology, and therapeutic drug action. Molecular imaging strategies and novel reporters now enable visualization of many drug targets and a few examples as outlined below demonstrate imaging of the proteasome and protein-protein interactions in living animals by bioluminescence and microPET. In addition, activity of the multidrug resistance (MDR1) P-glycoprotein membrane transporter and its inhibition can be observed in patients and animal models with radiotracers and bioluminescent substrates.
The ubiquitin-proteasome pathway is the central mediator of regulated proteolysis in cells, and defects in this pathway are associated with cancer and neurodegenerative diseases. To assess 26S proteasome function in living animals, we developed a tetra-ubiquitin-luciferase reporter for bioluminescence imaging. The reporter was degraded rapidly under steady-state conditions and stabilized in a dose-and time-dependent manner in response to proteasome inhibitors. Using bioluminescence imaging after one dose of the chemotherapeutic proteasome inhibitor bortezomib (PS-341), proteasome function in tumor xenografts was blocked within 30 min and returned to nearly baseline by 46 hr. However, after a 2-week regimen of bortezomib, imaging of target tumors showed significantly enhanced proteasome inhibition that no longer returned to baseline. The ubiquitin-luciferase reporter enables repetitive tissue-specific analysis of 26S proteasome activity in vivo and should facilitate development and validation of proteasome inhibitors in mouse models as well as investigations of the ubiquitin-proteasome pathway in disease pathogenesis.
Protein-protein interactions control transcription, cell division and cell proliferation as well as mediate signal transduction, oncogenic transformation and regulation of cell death. Although a variety of methods have been used to investigate protein interactions in vitro and in cultured cells, none can analyze these interactions in intact, living animals. To enable noninvasive molecular imaging of protein-protein interactions in vivo by positron emission tomography (PET) and fluorescence imaging, we engineered a fusion reporter gene comprising a mutant herpes simplex virus 1 thymidine kinase (HSV1-tk) and green fluorescent protein (GFP) for readout of a tetracycline-inducible 2-hybrid system in vivo. Using microPET, interactions between p53 tumor suppressor and the large T antigen (TAg) of SV40 virus were visualized in tumor xenografts of HeLa cells stably transfected with the imaging constructs. Imaging protein binding partners in vivo will enable functional proteomics in whole animals and provide a tool for screening compounds targeted to specific protein-protein interactions in living animals.
Multidrug resistance (MDR) mediated by overexpression of MDR1 P-glycoprotein (Pgp) is one of the best characterized barriers to chemotherapy in cancer patients. Furthermore, the protective function of Pgp-mediated efflux of xenobiotics in various organs has a profound effect on the bioavailability of drugs in general. Thus, there is an expanding requirement to noninvasively interrogate Pgp transport activity in vivo. We have developed and validated several radiopharmaceuticals that report the transport activity of Pgp in animals and patients noninvasively.
Imaging mechanisms of drug action directly at target sites in vivo and mechanisms of drug resistance that act directly on the disposition and targeting of drugs or indirectly on downstream regulators and effectors of therapeutic drug action will aid the discovery, development and use of anticancer agents.
